Latest News

Extended-release oral minoxidil candidate VDPHL01 improved hair counts and patient-reported outcomes in women with pattern hair loss in a phase 2 study.

This review of the latest dermatological studies includes insights on gut dysbiosis in inflammatory conditions, air pollution and vitiligo risk, emollient use in AD patients, and more.

New JCI research identifies succinate/SUCNR1 signaling as a potential mechanistic link between hyperglycemia and worsening vitiligo.

Low vitamin B12 levels link to longer-lasting wheals and heavier symptom burden in chronic spontaneous urticaria, suggesting a simple lab check for stubborn cases.

Clinicians at a Dermatology Times Case-Based Roundtable event worked through 3 vitiligo cases spanning new-onset, widespread, and pediatric disease, weighing treatment sequencing against real-world access barriers.

At a recent Dermatology Times Evolving Paradigms event led by Mark Nestor, MD, PhD, FAAD, dermatologists, Mohs surgeons, and oncologists compared immunotherapy mechanisms and referral thresholds for advanced CSCC.

Q32 Bio reported bempikibart reduced SALT scores by 35.3% and produced a SALT-20 response in 40.0% of patients at week 36 in the SIGNAL-AA phase 2a trial.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Do topical forms of PDRN actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

TRAPEDS-1 met its primary pharmacokinetic objective in children aged 6 to 11 years with moderate to severe atopic dermatitis, with no new safety signals over up to 172 weeks of tralokinumab treatment.

A new real-world study found CSU was linked to stress-related disorders, but not a broad increase in new-onset psychiatric disease.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!